Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKB-6548 and Ferrous Sulfate PK Study
NCT02327546Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Dec 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A), sponsored by Akebia Therapeutics. Primary endpoint: Maximum plasma concentration of AKB-6548. Started Dec 2014; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02327546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327546.